Dr. Tripathy on the Development of Palbociclib in Breast Cancer

August 24, 2015
Debu Tripathy, MD

Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.

Debu Tripathy, MD, chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses the development of palbociclib (Ibrance) in breast cancer.

Related Content:

VideosBreast Cancer
Shorter Adjuvant Trastuzumab Has Long-Term Benefits for HER2+ Breast Cancer
Tailored Survivorship Care Is Needed in the Breast Cancer Space
Genetic Testing May Increase Fear of Recurrence